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Abstract: Therapeutic resistance seen in aggressive forms of breast cancer remains challenging for
current treatments. More than half of the patients suffer from a disease relapse, most of them with
distant metastases. Cancer maintenance, resistance to therapy, and metastatic disease seem to be
sustained by the presence of cancer stem cells (CSC) within a tumor. The difficulty in targeting this
subpopulation derives from their dynamic interconversion process, where CSC can differentiate to
non-CSC, which in turn de-differentiate into cells with CSC properties. Using fluorescent CSC models
driven by the expression of ALDH1A 1(aldehyde dehydrogenase 1A1), we confirmed this dynamic
phenotypic change in MDA-MB-231 breast cancer cells and to identify Serine/Threonine Kinase 2
(AKT2) as an important player in the process. To confirm the central role of AKT2, we silenced
AKT2 expression via small interfering RNA and using a chemical inhibitor (CCT128930), in both CSC
and non-CSC from different cancer cell lines. Our results revealed that AKT2 inhibition effectively
prevents non-CSC reversion through mesenchymal to epithelial transition, reducing invasion and
colony formation ability of both, non-CSC and CSC. Further, AKT2 inhibition reduced CSC survival in
low attachment conditions. Interestingly, in orthotopic tumor mouse models, high expression levels
of AKT2 were detected in circulating tumor cells (CTC). These findings suggest AKT2 as a promising
target for future anti-cancer therapies at three important levels: (i) Epithelial-to-mesenchymal
transition (EMT) reversion and maintenance of CSC subpopulation in primary tumors, (ii) reduction
of CTC and the likelihood of metastatic spread, and (iii) prevention of tumor recurrence through
inhibition of CSC tumorigenic and metastatic potential.
Keywords: cancer stem cells (CSC); dynamic phenotype; epithelial-to-mesenchymal transition (EMT);
AKT2 targeting
1. Introduction
Drug resistance in breast cancer cell populations is acquired through phenotypic changes mediated
by either epithelial-to-mesenchymal transition (EMT), or tumor cell drift towards a cancer stem cell
(CSC) phenotype [1,2]. As a consequence of phenotypic dynamism and clonal evolution during the
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cancer treatment, tumors contain a heterogeneous mixture of various cell types, with different stem-like
and mesenchymal phenotypes. Moreover, in this intricate network made of diverse cell populations,
the characteristics of mesenchymal and stem-like phenotype are often intertwined, becoming difficult
to distinguish from one another [2–5]. EMT cells, as well as CSC, are described as responsible for
metastatic spread, tumor progression, and resistance. CSC also possesses a tumor initiating capacity
and cell renewal capacity, even though some mesenchymal cells have been shown to be able to initiate
tumor growth. Moreover, the EMT conversion stimulates expression of CSC genes and vice-versa,
thus CSC often expresses genes characteristic for mesenchymal cells [1,2,6].
Due to the high level of complexity, the investigation of dynamic phenotypic changes during
cancer development and/or treatment has proven technically challenging, and the use of in vitro
or in vivo models for this purpose are fairly limited. Permanently tagged CSC are able to mimic,
at least to some extent, the complexity of phenotypic dynamism in laboratory conditions. Previously,
we described CSC tagging based on an expression vector containing the tdTomato fluorescent protein
under the control of ALDH1A1 (aldehyde dehydrogenase 1A1) promoter [7]. Since ALDH1A1 is
expressed in CSC, this approach enables the identification and isolation of CSC, and has proved
successful for the MCF7 breast cancer cell line and HCT116 colon cancer cell line [7]. Here, we use the
same strategy to identify and trace CSC from the highly aggressive triple-negative breast cancer (TNBC)
cell line, MDA-MB-231. TNBC presents the overall worst prognosis, greater metastatic potential, and
higher relapse rate compared to other breast cancer types [8]. Sequential single-agent chemotherapy
remains the standard of care for patients with metastatic TNBC, since targeted therapies have failed
due to the lack of commonly targetable receptors (estrogen receptor (ER), progesterone receptor (PR),
and HER2/neu). Consequently, overall survival among patients with this form of breast cancer has
not changed over the past 20 years; this highlights the need for advances in therapeutic options for
these patients [9,10]. Two PARP (poly ADP ribose polymerase) inhibitors (Olaparib, Talazoparib) for
patients with BRCA-mutated tumors, and immunotherapy for patients with PD-L1 (programmed
death-ligand 1)—positive TNBC have been recently approved, but longer follow-ups are needed to
determine how these agents improve overall survival among patients with TNBC [11].
In this study, we explored the importance of the AKT2/TWIST and AKT2/mTOR axis for
CSCsurvival and malignancy. Even though AKT2 has previously been identified as a promising target
for cancer treatment, its role in determining CSC phenotype has not been addressed [12–14].
AKT2 was chosen for this study as the main subtype of the protein kinases B family. AKT2 has
been previously shown to have a direct relationship with malignant transformation and tumor
dissemination [15–17]. In contrast, cells transfected with AKT1 and AKT3 exhibit only minor alterations
in cell invasiveness and these isoforms do not appear to play a role during EMT [18,19]. Early works have
also demonstrated that siRNA (small interfering RNA) depletion of AKT2 results in reduced cell growth
and invasiveness, with MET only occurring in cells overexpressing AKT2, confirming its potential role in
tumorigenesis [20]. Even though AKT2 is not frequently over-amplified in breast cancer, its expression is
linked with poor prognosis. In contrast, no correlation has been detected with AKT1 or AKT3 in terms of
patients’ survival [21,22].
AKT2 is a major downstream effector of the canonical PI3-K (phosphoinositide 3-kinase) pathway,
which appears generally associated with acquisition of the malignant phenotype in cancer cells [17–19].
AKT/PKB is a key regulator of various cell processes and its signaling outcome depends on cellular
background and context. Similarly, all cancer-related molecular mechanisms are highly dependent on
cell type and phenotype. AKT2 may act via different signaling mechanisms; TWIST and mTOR being
the main downstream effectors of AKT2 [15,20,21]. Within the context of CSC, TWIST (twist family
bHLH transcription factor 1) arose as a very promising candidate due to its important and well-known
role in tumor invasion, migration, dissemination, and drug resistance [23,24]. Since TWIST-mediated
effects are regulated by AKT2, silencing of this oncogene could be explored as a potential strategy to
reduce TWIST-mediated EMT through decrease of E-CADHERIN expression [20,25]. Furthermore,
mTOR (mechanistic target of rapamycin kinase) signaling activation, as a result of increased activity
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of PI3K/AKT, significantly contributes to the initiation and development of tumors due to their
involvement in cell growth, proliferation, motility, invasion, and survival. In this context, mTOR activity
is found deregulated in many types of cancer including breast, prostate, lung, melanoma, bladder,
brain, and renal carcinomas [26,27]. Moreover, recent data also suggest that the PI3K/AKT2/mTOR
signaling pathway strongly modulates CSC biology [14,28–30]. Targeting the EMT signaling axis via
AKT2/TWIST and PI3K/AKT2/mTOR in order to revert EMT and restore the epithelial phenotype
appears to be a promising strategy in cancer therapy.
2. Results
2.1. Characterization and Dynamism of MDA-MB-231 CSC-Like Cell Model
In order to tag TNBC cells with a CSC phenotype, MDA-MB-231 cells were stably transfected with
ALDH1A1-tdTomato reporter vector, and flow sorted based on tdTomato fluorescence (Figure 1A,B).
Consecutive cell passages of tdTomato+ MDA-MB-231 cells led to an initial decline and then stabilization
of the tdTomato+ subpopulation (Figure 1C), which accounted for 14.7%± 2.8% of tdTomato+ cells within
the MDA-MB-231-ALDH1A1/tdTomato cell line (Figure 1B). The stem like nature of tdTomato+ cells was
confirmed by increased expression of stem cell markers compared to tdTomato− cells (Figure 1D).
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Figure 1. MDA-MB-231-ALDH1A1/tdTomato cancer ste cell (CSC) model. After transfection with
reporter vector ALDH1 1/tdTomato, CSC-like cells expres flu scent repo ter (tdTomato) under the
CSC-specific promoter (ALDH1A1). Scale bar represents 20 µm (A). This allows the CSC quantification
and sorting by fluorescence-activated cell sorting (FACS) (B). Sorted tdTomato+ cell population dropped
and stabilized over passages (C). We confirmed by qPCR, that tdTomato+ cells (CSC) express stem cell
markers. Results are expressed as NRQ (relative normalized quantities) mean ± SEM (n ≥ 3); * p < 0.05;
** p < 0.01, *** p < 0.001 (D).
Cancers 2019, 11, 1058 4 of 18
Briefly, the relative increase of ALDH1A1 mRNA in tdTomato+ CSC was 4.46± 0.53 fold (p = 0.025).
Other CSC markers, such NOTCH4, POU5F1/OCT4, ALOX5, CMKLRI, ABCG2, and CXCR1 were also
found over-expressed (1.78 ± 0.18, p = 0.01; 1.78 ± 0.09, p = 0.017; 2.42 ± 0.06, p = 0.04; 1.89 ± 0.12,
p = 0.02, 1.99 ± 0.08, p = 0.04; 3.1 ± 0.78, p = 0.034; fold, respectively). No difference in CD44 and CD24
mRNA levels were observed in MDA-MB-231 tdTomato+ cells compared to tdTomato− (non-CSC;
Figure S1A). Of note, overall expression of CD44 was high, and CD24 was low in MDA-MB-231 cells
according to their mesenchymal-stem like (MSL) characteristics (Figure S1B) [31].
As expected, tdTomato+ MDA-MB-231 CSC-like cells were able to grow as mammospheres in low
attachment cell culture conditions, when seeded in a medium without serum (Figure 2).
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Figure 2. Mammosphere culture of tdTomato+ cells. tdTomato+ CSC were able to form mammospheres
in low attachment plates, in serum free media. Scale bar represents 100 µm (A) tdTomato+ cells formed
significantly more ma mosph res than tdTomato− cells (B). *** p < 0.001
Nevertheless, the tdTomato− (non-CSC) cells were also able to grow in these conditions but
formed significantly fewer mammospheres than equivalent amounts of tdTomato+ cells (Figure 2,
Table 1). While tdTomato+ CSC-like cells start to form the mamm spheres when just 10 cells/well were
seeded (mammosphere incidence = 6/12; 50 (n/n, (%))), it was n cessary to seed at least 100 cel s/well of
tdTomato− non-CSC cells to induce mammosphere formation (mam ospher incidence = 1/8; 12 (n/n,
(%)). In contrast, 12/12; 100 (n/n, (%)) of i idence was observed when 100 CSC-like cells were seeded
per we l (Table 1).
Table 1. Incidence of mammosphere formation.
Initial Number of Cells
Per Well
Stemness
Type 1 3 10 30 100 300 1000
Mammosphere formation CSC-like − − + + + + +
Non-CSC − − − − + + +
Incidence of mammosphere
formation (n/n)
CSC-like N/A N/A 6/12 8/12 12/12 12/12 12/12
Non-CSC N/A N/A N/A N/A 1/8 4/10 7/12
Incidence of mammosphere
formation (%)
CSC-like N/A N/A 50% 67% 100% 100% 100%
Non-CSC N/A N/A N/A N/A 12% 50% 58%
n/n—number of wells with mammospheres per number of wells in total; N/A—not applicable.
Interestingly, when only the tdTomato− cell population was cultured in non-attachment conditions;
tdTomato+ cells appeared from day 7 within the cell culture (Figure 3). This was not due to a fast
proliferation of some residual CSC; since it was possible to observe a sudden switch to tdTomato+
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phenotype of the whole mammosphere (Figure S2). These “new” tdTomato+ cells expressed a
significantly higher amount of stem cell markers (ALDH1A1, NOTCH4, POU5F1/OCT4, ALOX5,
and CMKLR1) and had increased invasion potential, compared to sorted tdTomato− cells (Figure 3D,E).
Interestingly, the increase of tdTomato and stem cell gene expression in originally tdTomato− cells,
was just transient, since when “new” tdTomato+ CSC were cultured back in attachment conditions,
in complete medium (four days), the expression of tdTomato and stem cell markers decreased back to
normal and just few tdTomato+ cells (5.6%) were detected by flow cytometry (Figure 3). Analogously,
we observed de novo tdTomato expression and stem cell gene expression, as well as increased invasion
capacity, when using tdTomato− cells sorted from an aggressive HCT8 colon cancer cell line (Figure S3).
Of note, tdTomato− MCF7 epithelial cells did not survive in mammosphere culture conditions.Cancers 2019, 11, x FOR PEER REVIEW 6 of 19 
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Figure 3. MDA-MB-231 reversion process. Schematic representation of the experiment. Briefly, tdTomato−
(non-CSC) were placed in low attachment plates in FBS (Fetal Bovine Serum)-free culture medium and
were cultured for 7–17 days. During this time cells acquired the CSC phenotype. Afterwards, tdTomato+
cells were plated back into adherent plates in complete culture medium and were allowed to grow for
another four days (A). The cells were monitored over the time by fluorescent microscopy (B) and flow
cytometry (C). The stem cell properties of “new” tdTomato+ cells were confirmed by a change in stem
cell gene expression profile, measured by qPCR (D) and by an increase of invasive ability (E). Results
are expressed as NRQ (relative normalized quantities) mean ± SEM (n ≥ 3); (* p < 0.05; ** p < 0.01,
*** p < 0.001).
In order to determine the tumor initiating capacity of MDA-MB-231 tdTomato+ cells, sorted
tdTomato+, and tdTomato− cells were xenotransplanted into mice. Two groups (eight animals each)
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were injected with 1000 cells into their flanks, and tumors were allowed to grow for 71 days. Tumors
were detected in 8/8 animals in the group of tdTomato+ CSC, as expected, while just in 6/8 animals
that were xenotransplanted. In both cases, obtained tumor volumes were similar (Figure 4C). Ex-vivo
analysis of tumors showed expression of tdTomato (59.8% ± 5.3%) in all tumors of the CSC-like group.
However, the presence of tdTomato+ (17.79%) cells was confirmed by immunohistochemistry and flow
cytometry just in 1/6 tumors in animals injected with tdTomato− non-CSC cells (Figure 4).Cancers 2019, 11, x FOR PEER REVIEW 7 of 19 
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Figure 4. MDA-MB-231 in vi o model. Tumor growth and Kaplan–Mei r survi al curves of mice
inoculated inoculated orth topically into the right mammary f d pad (IMFP) with MDA-MB-231dTomato−
non-CSC (n = 6), and MDA-MB-231dTomato+ CSC (n = 8) cell variants was moni ored over time.
N statistically significant differe ces were detected (A). Summary of information egard g tumor
incidence, tumor growth, and tdTomato and TWIST expressi n within the tumor (B). Examples of IHC
(immunohistochemistry) (HE/td Tomato) in representative tu ors of animal i oculated with CSC-like
cells, and non-CSC (tdTomato positive as well as he tdTomat negative example). Magnification bar
represents 100 µm (C).
2.2. Involvement of AKT2 in Dynamism of EMT and CSC-Like Phenotype
The observation of relatively high incidence of tumors derived from MDA-MB-231 tdTomato−
cells, with low incidence of “new” tdTomato+ CSC-like cells, made us wonder whether there is another
type of phenotypic dynamism, for instance EMT, involved in the process of tumorigenesis. Notably,
we observed more EMT genes (low E-CADHERIN, high FIBRONECTIN, and high VIMENTIN) in the
tumors derived from non-CSC compared to tumors derived from CSC-like tdTomato+ cells (Figure 5A).
NOTCH4, an important EMT and CSC marker, was also highly over-expressed in the tumors derived
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from MDA-MB-231 non-CSC. Besides, mTOR, an AKT2 downstream gene was also over-expressed in
these tumors, compared to tumors derived from tdTomato+ cells (Figure 5A).
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Figure 5. AKT2/TWIST/mTOR axis in vivo and in vitro. Gene expression in the tumors derived
from non-CSC relative to tu ors derived from CSC-like tdTomato+ cells (A). Dissociation curve plot
confirmed that tumors expressed TWIST, even though the injected cells did not express TWIST per se
(B). Gene expression in circulating tumor cells (CTCs) isolated from the blood of tumor bearing animals
relative to gene expression of tumors (C). Gene expression in low attachment culture conditions, relative
to the same cells cultured i monolayer (D). qPCR results are expressed as NRQ (relative normalized
quantities) mean ± SEM (n ≥ 3); (* p < 0.05; ** p < 0.01).
TWIST, an AKT downstream gene, has been previously described as responsible for mesenchymal
to epithelia switch. Even though inj cted MDA-MB-231 cells completely lack TWIST expression, 5/6
(83%) tumors derived from tdTomato− MDA-MB-231 c lls expressed TWIST (Figure 4B). In the group
of CSC-like injected animals, just 3/7 (42%) express TWIST in the resultant tumors (Figure 4, Figure 5B).
AKT2mRNA expressi n level was however ot changed within the different groups (Figure S4). Of note,
we detect d a s nificant increase of AKT2 mRNA expression (FC = 2.3 ± 0.32, p = 0.01) in circulating
tumor cells (CTC) isolated from the blood of tumor bearing animals. In addition, CTCs derived from
tumors also expressed high levels f mTOR (F = 2.3 ± 0.26, p = 0.02) and TWIST (FC = 2.6 ± 0.28,
p = 0.03) compared to prima y tumors (Figure 5C). This was accompanied by significant decrease of
E-CADHERIN expression (FC = 0. 7 ± 0.13, p = 0.02) (Figu e 5C).
Further exploration of the AKT2/TW ST/mTOR axis in mammospheres, resembling CTCs in vitro,
revealed MDA-MB-231 cells in low attachment expressed significantly higher level of AKT2 (FC = 2.4
± 0.19, p = 0.00003) and mTOR (FC = 1.9 ± 0.05, p = 0.0003), compared with the same cel s cultured
in monolayer (Figure 5D). Moreover, these gene expression levels decreased when the c ll w re
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cultured again in attachment conditions (Figure 5D). Expression of TWIST mRNA was not detected in
these conditions.
Interestingly, AKT2 expression was not altered in CSC fraction either in MDA-MB-231 cells or in
MCF7 cells. In fact, none of the AKT isoforms (AKT1, AKT2, and AKT3) were differentially expressed
in the CSC fraction compared with the non-CSC fraction (Figure S5, Text S2).
2.3. Consequences of AKT2 Inhibition for CSC-Like/EMT Phenotype
The increased expression of EMT genes (AKT2, TWIST, and mTOR) in tdTomato− tumors, in CTCs
and in mammospheres, highlights the importance of AKT2 in tumor growth and CSC malignancy.
To pursue this line of investigation further, we explored the consequences of AKT2 silencing in three
different cancer cell lines, and their CSC-like fractions (MDA-MB-231, HCT8, and MCF7). Even though
the suitability of AKT2 targeting in general terms is well known, its role in CSC malignancy has not
been elucidated yet [17–19,25,32].
Since AKT2 is known to play an important role in EMT, and is a likely candidate for driving
the CSC phenotype, we first characterized mesenchymal gene expression levels in the investigated
cells lines. CSC isolated from the mesenchymal cell lines MDA-MB-231 did not differ in EMT gene
expression that was high in both “bulk” fraction as well as in CSC-like fraction (Figure 6A). In contrast,
CSC isolated from epithelial cell lines (MCF7, HCT8) showed increased mesenchymal phenotype (low
E-CADHERIN, high VIMENTIN, and FIBRONECTIN) compared to their respective “bulk” counterparts
(Figure 6A). In addition, mesenchymal, stem-like cell lines SKBR3 and MDA-MB-468 were included in
the analysis, as well.
Specific inhibition of AKT2 by siRNA reduced AKT2 mRNA expression by 80% in all cell lines
used, while no effect on AKT1 isoform expression was detected (Figure S6). Downregulation of AKT2
was also confirmed at the protein level by Western Blot (WB) (Figure 7).
As expected, sorted CSC subpopulations showed significantly higher capacity for anchorage-
independent growth compared to non-CSC fractions, further confirming the CSC nature of tdTomato+
cells (Figure 6B). Similarly, CSC from MDA-MB-231 and MCF7 showed significantly higher invasive
potential. No difference in invasion was detected between CSC and non-CSC in HCT8 cell line (Figure 6C).
For MDA-MB-231 and HCT8, AKT2 silencing significantly reduced the number of cells able to
grow without anchorage, and the invasive potential of both CSC and non-CSC. In the case of MCF7,
anchorage-independent growth capacity and invasive ability was strongly reduced after AKT2 silencing
only in the CSC subpopulation (Figure 6B,C). Moreover, anchorage-independent growth and invasion
were significantly reduced also in breast cancer cell lines with clear mesenchymal phenotype; with high
expression of ALDH1A1, (MDA-MB-468 and SKBR3) after AKT2 silencing (Figure S7A,B). Furthermore,
we observed a significant impairment of cell migration and proliferation of the mesenchymal cells
in which AKT2 was silenced, in MDA-MB-231, MDA-MB-468, and SKBR3 cell lines (Figure S7C,D).
In contrast, no difference in the migration and proliferation of “bulk” epithelial MCF7 cells was
observed after AKT2 silencing (Figure S8B,C).
To explain mechanistically the downstream effect of AKT2 silencing in different cell types, and
in CSC-like cells derived from these cell lines, is however not straightforward. We observed different
pathway involvement depending on the cellular background. In mesenchymal (MDA-MB-231) as well as
epithelial (HCT8) cell lines that do not express TWIST in vitro, the predominant effect on AKT2 inhibition
was de-regulation of mTOR signaling (p.53, GSK3b high) (Figure 7A), whereas in mesenchymal cell lines
that do express TWIST (MDA-MB-468, SKBR3), and in mesenchymal CSC isolated from epithelial MCF7
cells, AKT2 inhibition caused the reversion of mesenchymal to epithelial phenotype (E-CADHERIN high,
and N-CADHERIN, VIMENTIN, and FIBRONECTIN LOW; Figure 7B,C). No clear effects on EMT genes
and mTOR pathway signaling were observed in MCF7 bulk cells, even though TWIST and mTOR mRNA
were downregulated in these cells after AKT2 inhibition (Figure S8A).
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HCT-8, and MCF-7 CSC were separated from non-CSCs and the relative EMT gene expression
profile was quantified by qPCR. The presented values are relative to their non-CSC population
(A). Anchorage-independent growth assay: The graph represents the number of cells capable of
anchorage-independent growth, comparing CSCs and non-CSC transfected with siAKT2 and control
siRNA (siC). Images are photographs of colonies formed after seven days of incubation with siAKT2
and siC (B). Invasion assay: The graph represents the number of cells that demonstrated invasive
capacity comparing CSC and non-CSC transfected with siAKT2 and siC (C). Results are expressed as
NRQ (relative normalized quantities) mean ± SEM (n ≥ 3); (* p < 0.05; ** p < 0.01, *** p < 0.001).
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Furthermore, we observed also down-regulation of E-CADHERIN and some stem cell genes (OCT4,
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Finally, we tested the capability of an AKT2-specific inhibitor, CCT128930, to inhibit mammosphere
growth, s a proof of concept for the fur her development of nano-therapies based on AKT2 inh bit on
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and the resulting EMT and CSC phenotype, blockade. Furthermore, AKT2 inhibition using siRNA
was not optimal in low attachment cell culture, but CCT128930 be used in these conditions. However,
when inhibiting AKT2 with CCT128930, we observed a progressive cell death in a dose dependent
manner, that was quantified using DAPI (4′,6-Diamidine-2′-phenylindole dihydrochloride) vital
staining (Figure 8).
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Figure 8. Effect of AKT2 chemical inhibition (CCT128930) on mammosphere growth. Sorted
MDA-MB-231 tdTomato− cells were plated in serum free low attachment conditions, in the presence of
6.25 µM, 12.5 µM, and 25 µM of CCT128930 and the formation of tumorspheres was monitored over
time. ith increasing concentrations of CCT128930, there were fewer tumorspheres, of smaller size,
(A) and we detecte sing proportions of dead (DAPI+) cells by flow cytometry (B).
3. Discussions
The MDA-MB-231 cell line is a mo ighly a gressive TNBC. This cell line is cat gorized
as a mes nchymal stem cell li cell line an displays igh expression of CD44 and low expression
of CD24, which is a common signature of breast CSC and at the same time it is an indication of the
mesenchymal origin of these cells. Besides, MDA-MB-231 cells are highly proliferative with elevated
migratory capacity, and as few as 1000 cells can produce a tumor in vivo with metastatic dissemination.
To our best knowledge, the MDA-MB-231 CSC model has not been described previously either in vitro
or in vivo. This is probably due to the high complexity of this cell line and no clear boundaries between
the EMT and CSC phenotype of MDA-MB-231 cells. CSC within this cell line had been identified just
by surface markers, specific inhibition, or their adhesion properties [33–36]. We were however able to
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distinguish a unique population of CSC-like cells within the bulk cell line based on ALDH1A1-tdTomato
expression vector. Accordingly, tdTomato+ CSC-like cells express stem cell markers and have higher
invasive and transformative potential compared to tdTomato− non-CSC [7,33].
Nevertheless, we detected a high level of phenotype dynamism in the tdTomato− cells,
corresponding to the non-CSC fraction. These cells were also able to form mammospheres in
low attachment conditions, even though in a lower extent than tdTomato+ CSC-like cells. Interestingly,
the non-CSC fraction became tdTomato+ during the process and CSC genes expression was significantly
increased, confirming once again the close EMT–CSC connection. The phenomenon of dynamic CSC
phenotype was initially predicted by a mathematical Markov model and was later corroborated
experimentally in vitro and in vivo [3,5,37–39]. Accordingly, after successful anti-CSC treatment,
the remaining non-CSC tumor cells can change their phenotype to CSC-like phenotype in order to
ensure tumor progression [5–7]. Similar behavior was observed also in vivo; tdTomato− cells originated
a tumor containing tdTomato+ cells. However, this occurred just in one out of six in vivo models.
In the rest of the tumors we did not detect clear tdTomato expression, although these tumors showed
increased EMT gene expression and NOTCH4 expression. Evidently, there was an adaptation of
the phenotype; since we detected “de novo” TWIST expression despite the fact that MDA-MB-231
cells before injection did not express this gene. Since other EMT genes (low E-CADHERIN, high
VIMENTIN, and N-CADHERIN) and mTOR were also overexpressed in these tumors, we speculated
whether AKT2, the mastermind of TWIST and mTOR was responsible for these phenotypic changes.
AKT2 and mTOR was also overexpressed in mammosphere cell culture, however, their expression
as well as stem cell marker expression, lowered after returning the cells to attachment conditions.
This observation supports dynamism based on growth conditions, in order to survive [5–7]. AKT2
is a well-known target for cancer treatment, and we have demonstrated its importance for CSC
growth and dynamism in breast cell lines, suggesting that AKT2 could be an ideal candidate for
an effective anti-cancer therapy [12,30]. We have provided evidence that the inhibition of AKT2
not only affects “bulk” tumor cells, but also inhibits CSC survival in low attachment conditions.
Additionally, AKT2 down-regulation inhibited the invasion and transformation capacity of both cells
(bulk and CSC-like cells). Since invasiveness is related to several distinct cellular functions including
adhesion, motility, and detachment, the regulation of EMT should hamper the invasive properties
of cells [40]. Malignant transformation occurs via a series of genetic and epigenetic alterations that
allow the tumor cell population to proliferate independently of both external and internal signals that
normally restrain growth. Likewise, CSCshow reduced requirements for adherent-dependent growth
and are not restricted by cell–cell contact [41]. The increased expression of E-CADHERIN caused by
EMT reversion, overturns this capacity for unregulated proliferation. Accordingly, invasiveness and
malignant transformation of cells was affected by AKT2 silencing only in mesenchymal cells (CSC,
bulk cells), while no changes were observed in the epithelial MCF7 cell line. Similarly, proliferation
and migration of “bulk” epithelial MCF7 was not affected, while mesenchymal cells (MDA-MB-231,
MDA-MB-468, and SKBR3) showed decreased cell migration and proliferation after AKT2 inhibition.
Since MCF7 cells normally display an epithelial phenotype (high E-CADHERIN, low FIBRONECTIN,
and low VIMENTIN), MET (mesenchymal-to-epithelial transition) triggered via AKT2 silencing had no
effect on “bulk” MCF7 cell population. However, CSCsubpopulations isolated from MCF7 epithelial
cell line presented a more mesenchymal phenotype than the non-CSC, mainly by a decrease in
E-CADHERIN expression, and an increase in VIMENTIN and FIBRONECTIN expression. In this
mesenchymal CSC fraction (1–2%) isolated from epithelial MCF7 cells we witnessed the impact of
AKT2 silencing in terms of reduced transformation and invasive capacity. Since these CSC are thought
to be responsible for tumor growth and maintenance, curtailment of their tumorigenic capacity could
prevent tumor progression. We speculated that an effective therapy could consist of standard therapy
in combination with AKT2 inhibition, to completely eradicate all cancer cells.
Furthermore, a high level of AKT2 expression was observed also in circulating tumor cells (CTCs)
in vivo. Thus, we hypothesized that targeting AKT2 could be effective in multiple levels; it may
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diminish invasiveness and transformative potential of CSC, to revert the mesenchymal phenotype of
aggressive tumor cells back to a more epithelial type, and to reduce of the incidence of CTCs in the
bloodstream and the concomitant opportunity for metastatic spread.
In this study we focused on AKT2, since it is the only isoform of AKT associated with EMT
and tumor dissemination. Besides, its over-expression positively correlates with poor survival rates.
The role of AKT1 and AKT3 in breast cancer should be studied as well, because these isoforms have
distinctive and non-redundant activities [15,21,42]. In particular, expression of AKT3 has been recently
associated with TNBC tumors [22]. Yet, its role in tumor progression is controversial as some studies
have showed an inhibitory effect of AKT3 on cell migration and invasion [19].
Our data did not allow us to reach a clear conclusion regarding the downstream pathways that
were affected in these processes by targeting AKT2. Since the AKT2/TWIST/mTOR signaling axis
was involved in many processes, its exact mode of action depended on the cellular background,
the clonal evolution, and CSC state among others. It is likely that AKT2 inhibition could affect a broad
spectrum of downstream pathways; although there are always some common cellular responses: (i) An
inhibition of growth, (ii) an inhibition of invasiveness, and (iii) an inhibition transformation potential.
Therefore, inhibition of AKT2 could potentially be a good candidate for breast cancer treatment and
should be further analyzed to probe its therapeutic use. In fact, numbers of small molecule inhibitors
targeting various components of the PI3K/AKT pathway are already in clinical development and
evaluation (e.g., Afuresertib (GSK2110183), AZD5363, BAY1125976, Ipatasertib (GDC-0068), MK-2206,
etc.). Given the multiple feedback loops within the PI3K-AKT signaling pathway, dual inhibition at
different levels is also under investigation (e.g., gefitinib, erlotinib, and ridaforolimus with MK-22069,
respectively). Despite the demonstrated clinical benefits of these treatments, their over-lapping
toxicities preclude required dosage. One method to overcome current drawbacks in regards of toxicity
and effective dosage is the development of delivery systems for siAKT2, and AKT2 inhibitors targeted
to malignant cells [43,44]. Nanomedicine can facilitate the administration of hydrophobic agents
and/or siRNA, while protecting them during circulation, lowering the undesired side effects associated
with systemic, non-controlled distribution of the drug. Nanomedicines can also evade multi drug
resistant mechanisms (i.e., MDR channels) and increase drug’s intracellular accumulation, improving
the efficacy of the treatment [45,46]. More advanced delivery systems could be used to combine several
inhibitors of AKT2/TWIST/mTOR pathway to synergize treatment efficacy, improve clinical outcomes,
and overcome resistance to treatments, while protecting somatic cells from undesired toxicities.
4. Materials and Methods
4.1. Cell Culture
Breast (MCF-7, MDA-MB-231, MDA-MB-468, and SKBR3) and colon (HCT8 and HCT116)
cancer cell lines were obtained from American Type Culture Collection (ATTC, LGC Standards,
Barcelona, Spain; Table S1). Detailed culture conditions are described in the supplemental information
(Supplementary Materials—Text S1).
4.2. Generation of CSC Models
CSC models were generated from breast and colon tumor cell lines as previously reported by our
group [7]. Briefly, tdTomato reporter cDNA was cloned under the minimal ALDH1A1 promoter using a
pENTRtm 5′-TOPO® TA Cloning Kit (Thermo Fisher Scientific, CA, USA) and tdTomato fluorochrome
was used as a reporter of ALDH1A1 promoter activity. Cells were transfected with Lipofectamine
2000 (Thermo Fisher Scientific, CA, USA), and cultured under selective pressure with 10 µg/mL
Blasticidin for two weeks. Positive tdTomato cells (tdTomato+) were sorted by fluorescence-activated
cell sorting (FACS) and reseeded to reproduce the parent cell line in which tumoral non-CSC showed
no expression of tdTomato (tdTomato−). Expression of known stemness markers (ALDH1A1, NOTCH4,
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POU5F1/OCT4, ALOX5, CMKLRI, ABCG2, CXCR1, CD44, and CD24) was used to determine the
stemness profile of cells.
Further, tdTomato+ cells were tested for their capacity to form tumorspheres when growing
in non-attachment conditions. For this, a maximum of 10.000 cells/mL were cultured 7–10 days in
ultra-low attachment plates in serum-free RPMI 1640 Medium (1X, Life Technologies) supplemented
with 6% glucose, 10 uL/mL L-GglutamaxTM, 10 uL/mL antibiotic-antimitotic mixture (Thermo Fisher
Scientific, CA, USA), 4 µg/mL heparin (Sigma, MI, USA), 2 mg/mL BSA, 0.02 ug/mL EGF (Sigma, MI,
USA), and 0.01 µg/mL FGFb (Thermo Fisher Scientific, CA, USA), and 10 µg/mL putrescin, 0.1 mg/mL
apo-transferrin, 25 µg/mL insulin, 30 µM selen, and 20 µM progesterone (all from Sigma, MI, USA).
We used p.96 low attachment plates to grow the exact number of cells (1, 3, 10, 30, 100, 300,
and 1000) sorted by FACS.
Similarly, sorted tdTomato negative (tdTomato−) populations were cultured in non-attachment
conditions for 17 days, and plated again into normal culture dishes for a further four days (diagrammatic
representation in Figure 4A).
4.3. Fluorescence-Activated Cell Sorting (FACS)
FACS was used to sort CSC and non-CSC subpopulations from a heterogeneous population of
MCF-7, MDA-MB-231, and HCT-8 cells. For cell sorting, a starting amount of 5X106 cells were used.
Cells were detached and resuspended in phosphate buffered saline (PBS; Lonza, Porriño, Spain),
supplemented with 10% Fetal Bovine Serum (FBS). DAPI (1 µg/mL, Life Technologies) was used for
vital staining (Life Technologies). Cells were sorted according to tdTomato and DAPI expression in
a FACS Aria cell sorter (BD Biosciences, CA, USA). Sorted cells were collected in complete medium
without antibiotic and used for subsequent experiments.
4.4. RNA Extraction and Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted from cells using an RNeasy Micro Kit (Qiagen, BCN, Spain) and
the RNA obtained was reverse transcribed using a High Capacity cDNA Reverse Transcription Kit
(Thermo Fisher Scientific, CA, USA) according to the manufacturer′s instructions. The cDNA reverse
transcription product was amplified with specific primers (Table S2) by qPCR using a SYBR Green
method (Thermo Fisher Scientific, CA, USA). The reaction was performed in triplicate on a 7500 Real
time PCR system (Thermo Fisher Scientific, CA, USA). Actin and S18 were used as endogenous controls.
Relative mRNA levels were calculated using the comparative Ct method (2e−∆∆Ct) [47].
4.5. In Vivo Tumorigenic and Metastatic Capacity Assay
Female NOD.CB17-Prkdcscid/J mice (Charles River, MA, USA) were kept in pathogen-free
conditions and used at six weeks of age. Animal care was handled in accordance with the Guide for the
Care and Use of Laboratory Animals of the Vall Hebron University Hospital Animal Facility, and the
experimental procedures were approved by the Animal Experimentation Ethical Committee at the
institution (approval number CEA-OH/9467/2). All the in vivo studies were performed by the Unique
Scientific and Technical Infrastructures (ICTS) “NANBIOSIS”, more specifically at the Bioengineering,
Biomaterials and Nanomedicine Research Center (CIBER-BBN) in vivo Experimental Platform of the
Functional Validation and Preclinical Research (FVPR) area (http://www.nanbiosis.es/portfolio/u20-
in-vivo-experimental-platform/; Barcelona, Spain). MDA-MB-231.Fluc2-C19.ALDH1-tdTomato+ at
1000 cells in 50 µL sterile PBS: Matrigel (1:1) were inoculated orthotopically into the right mammary fad
pad (IMFP; n = 8). Tumor growth was monitored twice a week by conventional caliper measurements
(D × d2/2, where D is the major diameter and d the minor diameter). Once primary tumors reached a
tumor volume range between 250–450 mm3, tumors were excised, weighted, and divided into several
fragments for FACS analyses. One additional sample was fixed with 4% formaldehyde and paraffin
embedded for histopatological analysis. At termination, blood samples were drawn from each animal
by cardiac puncture. Whole blood was transferred directly into commercial EDTA containing tubes and
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processed immediately to isolate circulating tumor cells (CTC). Briefly, blood samples were subjected to
several cycles of hemolysis using mixture of 90% of 16 M NH4Cl and 10% of 0.17 M Tris (pH 7.65) and
centrifuged. White blood cell pellets were then examined by flow cytometry (Fortessa, BD Biosciences,
CA, USA). Data were analyzed with FCS Express 4 Flow Research Edition software (De Novo Software,
Glendale, CA, USA).
4.6. AKT2 Inhibition
siRNAs were designed by Shanghai Gene Pharma (Shanghai, China). The sense AKT2
siRNA sequence used was 5′-GCUCCUUCAUUGGGUACAATT-3′, while a non-specific sequence
5′-UUCUCCGAACGUGUCACGUTT-3′ was used as a control (control siRNA). The siRNAs were
transfected into cells using Lipofectamine 2000 (Thermo Fisher Scientific, CA, USA). Transfections
were done in six-well plates with 2 × 105 cells per well, with a final concentration of 50 nM of siRNA in
antibiotic-free medium. The medium was changed 6 h after the transfection and cells were harvested
72 h after transfection. In the case of the non-CSC to CSC reversion experiments, AKT2 was inhibited
with the specific inhibitor CCT128930. Briefly, sorted MDA-MB-231 tdTomato− cells were plated in
serum-free low attachment conditions, in the presence of 6.25 µM, 12.5 µM and 25 µM of CCT128930
(Selleckchem, TX, USA) and the formation of tumorspheres was monitored over time.
4.7. Protein Extraction and Western Blotting
Cell pellets were lysed with Cell Lytic M reagent (Sigma, MI, USA)) containing a protease
inhibitor cocktail (Sigma, MI, USA). Proteins in crude lysates were quantified using the bicinchoninic
acid assay (BCA) Protein Assay (Pierce Biotechnology, MA, USA)). A total of 20 µg of whole-cell
lysates were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Merck Millipore,
Madrid, Spain). Blots were probed using primary antibodies (Table S3). Proteins were detected using
horseradish peroxidase (HRP)-conjugated secondary antibodies, anti-mouse (P0447, Dako, Barcelona,
Spain) or anti-rabbit (P0217, Dako, Barcelona, Spain), incubated for 1 h at room temperature. Band
intensity on the blots was quantified using the GeneTools Program (SynGene, Cambridge, UK).
4.8. Cell Transformation Assay (Anchorage-Independent Growth Assay)
Anchorage-independent growth of the different cancer cell lines was assessed using the CytoSelect™
Cell Transformation Assay Kit (Cell Biolabs, CA, USA). A semi-solid agar media was prepared accordingly
to the manufacturer’s instructions. Lipofectamine-AKT2-siRNA or Lipofectamine-Control-siRNA was
added to each well respectively. After 6–8 days of incubation the colonies were observed under the
microscope and viable transformed cells were counted using trypan blue.
4.9. Invasion Assay
The invasiveness of MDA-MB-468 and SKBR3 cells was assessed using the CytoSelect™ Laminin
Cell Invasion Assay Kit (Cell Biolabs, CA, USA). The polycarbonate membrane inserts were coated with a
uniform layer of Laminin-I and used to discriminate invasive from non-invasive cells. Whereas invasive
cells are able to degrade the laminin matrix layer and pass through the pores of the polycarbonate
membrane to the bottom of the insert membrane, non-invasive cells remain in the upper chamber.
Briefly, inserts were placed in a 24 well plate and cell suspensions containing 1× 106 cells/mL previously
transfected with AKT2 siRNA or control siRNA, added to the insert. After 48 h incubation, invasive
cells were dissociated from the lower side of the membranes, lysed, and quantified using CyQuant®
GR Fluorescent Dye (Cell Biolabs, CA, USA).
Statistical Analysis
Statistical analysis was performed using unpaired Student′s t-test. Differences were regarded as
statistically significant when the p-value was smaller than 0.05.
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5. Conclusions
Advanced cancers adapted very well to therapeutic challenges in order to survive under stress
conditions. Cells within the tumor often underwent dynamic phenotypic changes. We provided here
a CSC fluorescent model of the MDA-MB-231 cell line, in which these constant changes could be
observed in vitro as well in vivo. We focused our attention on AKT2 expression, which was elevated
in low attachment growth conditions of mammospheres and in circulating tumor cells. We suggest
that AKT/TWIST/mTOR pathway should be targeted to affect (i) CSC survival, (ii) “bulk” tumor cells,
and (iii) the non-CSC to CSC reversion phenotype (using additional CSC cell lines).
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